An optimized, amplicon-based approach for sequencing of SARS-CoV-2 from patient samples using COVIDSeq assay on Illumina MiSeq sequencing platforms.
Bioinformatics
Clinical Protocol
Genomics
Immunology
Microbiology
Sequence analysis
Sequencing
Journal
STAR protocols
ISSN: 2666-1667
Titre abrégé: STAR Protoc
Pays: United States
ID NLM: 101769501
Informations de publication
Date de publication:
17 09 2021
17 09 2021
Historique:
pubmed:
10
8
2021
medline:
10
8
2021
entrez:
9
8
2021
Statut:
ppublish
Résumé
Sequencing of SARS-CoV-2 genomes is crucial for understanding the genetic epidemiology of the COVID-19 pandemic. It is also critical for understanding the evolution of the virus and also for the rapid development of diagnostic tools. The present protocol is a modification of the Illumina COVIDSeq test. We describe an amplicon-based next-generation sequencing approach with short turnaround time, adapted for bench-top sequencers like MiSeq, iSeq, and MiniSeq. For complete details on the use and execution of this protocol, please refer to Bhoyar et al. (2021).
Identifiants
pubmed: 34368787
doi: 10.1016/j.xpro.2021.100755
pii: S2666-1667(21)00461-5
pmc: PMC8326003
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100755Informations de copyright
© 2021.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
PLoS One. 2021 Feb 17;16(2):e0247115
pubmed: 33596239
Bio Protoc. 2021 Apr 20;11(8):e3999
pubmed: 34124300